Innovation and How This Can Benefit the Rare Disease Community with Baroness Blackwood
As part of the NHS Long-Term Plan seriously ill children who are likely to have rare genetic disorders and adults suffering from certain rare conditions will begin to be offered whole genome sequencing in 2019. Further to this, Baroness Blackwood announced in February this year the development of The National Genomic Healthcare Strategy. This strategy will set out how the genomics community can work together to make the UK the global leader in genomic healthcare. During the announcement, Baroness Blackwood said that this strategy will aim to help diagnose illnesses before symptoms occur and use data and technology to prevent illnesses, not just treat them. This lunch meeting will discuss how innovation, data and technology can help achieve these goals and benefit the rare disease community.
Date: Thursday 24th October 2019
Time: 12.00pm – 3.00pm
Location: CMS London, 78 Cannon Street, London, EC4N 6AF
Baroness Nicola Blackwood
Baroness Blackwood was appointed as a Parliamentary Under Secretary of State at the Department of Health and Social Care on 10 January 2019. She previously served as Parliamentary Under Secretary of State at the Department of Health from July 2016 until June 2017. She was elected as the Conservative MP for Oxford West and Abingdon in May 2010.
IQVIA is a leading global provider of information, innovative technology solutions and contract research services dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients. Solutions are powered by the IQVIA CORE™, which combines big data, advanced technology, analytics and extensive industry knowledge. Formed through the merger of IMS Health and Quintiles, IQVIA has approximately 55,000 employees worldwide.
Discovery, innovation, market awareness and understanding are key to those life sciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.
Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, CMS provides complex legal and regulatory advice to launch, maintain and deliver products and services to the market.
We will be serving a buffet lunch. Please let us know of any dietary requirements.
Please RSVP by Friday 18th October using the link or for any questions please email Account Executive Christie Oliver at firstname.lastname@example.org or call 020 7839 9305.
Invitations are strictly by invitation only and non-transferrable.
- 24 Oct, 2019 12:00 - 15:00 BST
- CMS London 78 Cannon Street, London, EC4N 6AF See map